10x Genomics, Inc. — Director's Dealing 2020

Aug 5, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: 10x Genomics, Inc. (TXG)
CIK: 0001770787
Period of Report: 2020-08-03

Reporting Person: McAnear Justin J. (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-08-03	Class A Common Stock	M	10000	$5.04	Acquired	10933	Direct
2020-08-03	Class A Common Stock	S	2852	$98.8486	Disposed	8081	Direct
2020-08-03	Class A Common Stock	S	6348	$99.3863	Disposed	1733	Direct
2020-08-03	Class A Common Stock	S	800	$100.7625	Disposed	933	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-08-03	Stock Option (right to buy)	$5.04	M	10000	Disposed	2028-11-02	Class A Common Stock (10000)	Direct

Footnotes

F1: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F2: Includes 933 shares acquired under the Issuer's 2019 Employee Stock Purchase Plan on May 14, 2020.

F3: This transaction was executed in multiple trades at prices ranging from $98.09 to $99.08. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F4: This transaction was executed in multiple trades at prices ranging from $99.09 to $100.00. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F5: This transaction was executed in multiple trades at prices ranging from $100.40 to $101.31. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F6: This option, originally for 600,000 shares, of which 60,000 shares have been exercised, vested as to one-fourth of the shares on October 8, 2019 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.